Raman Mahajan

Raman Mahajan

Auto-generated profile, based on publicly available information

Raman Mahajan

Médecins Sans Frontières, New Delhi, India

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in The American Journal of Clinical Nutrition
Verified
Journal Article
Open access
PDF file
SBSakib Burza
Sakib Burza
RMRaman Mahajan
Raman Mahajan
EMElisa Marino
Elisa Marino
TSTemmy Sunyoto
Temmy Sunyoto
CSChandra Shandilya
Chandra Shandilya
KMKripa Nath Mishra
Kripa Nath Mishra
Background: An estimated one-third of the world’s children who are wasted live in India. In Bihar state, of children <5 y old, 27.1% are wasted an

2 September 2011 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
PSPrabhat K. Sinha
Prabhat K. Sinha
JGJohan Van Griensven
Johan Van Griensven
KPKrishna Pandey
Krishna Pandey
NKNawin Kumar
Nawin Kumar
NVNeena Verma
Neena Verma
PPPedro Pablo Palma
Pedro Pablo Palma
Background. Reports on treatment outcomes of visceral leishmaniasis (VL)–human immunodeficiency virus (HIV) coinfection in India are lacking. To our knowledge, none have studied the efficacy of liposomal amphotericin B in VL-HIV coinfection. We report the 2-year treatment outcomes of VL-HIV–coinfected patients treated with liposomal amphotericin B followed by combination antiretroviral treatment (cART) in Bihar, India. Methods. The study included all patients with newly diagnosed VL-HIV coinfection and initiating treatment with liposomal amphotericin B (20–25 mg/kg in 4–15 days) between July 2007 and September 2010. Kaplan–Meier estimates of the cumulative incidence of death/treatment failure were calculated. Results. Fifty-five patients were included (83.6% male; median age, 35 years; 62% migrant laborers; median follow-up, 1 year). The median CD4 cell count at VL diagnosis was 66 cells/μL (interquartile range, 38–112). Twenty-seven patients (49.1%) presented with VL relapse of VL. The overall tolerance of liposomal amphotericin B was excellent, with no interrupted treatment. Survival by 1 and 2 years after VL treatment was estimated at 85.5%. No patients had initial treatment failure. The probabilities of VL relapse were 0%, 8.1%, and 26.5% at 0.5, 1, and 2 years after VL treatment, respectively; relapse rates were similar for primary VL and VL relapse. CD4 counts <200 cells/μL at 6 months after cART initiation were predictive of subsequent relapse. The mean CD4 cell counts at 6 and 24 months after cART initiation were 187 and 261 cells/μL, respectively. The rate for retention in HIV care was 83.6%. Conclusions. Good long-term survival and retention rates were obtained for VL-HIV–coinfected patients treated with liposomal amphotericin B and cART. Although the initial VL treatment response was excellent, VL relapse within 2 years remained frequent.

2 January 2014 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
SBSakib Burza
Sakib Burza
PSPrabhat K. Sinha
Prabhat K. Sinha
RMRaman Mahajan
Raman Mahajan
MLMaría Angeles Lima
María Angeles Lima
GMGaurab Mitra
Gaurab Mitra
PDPradeep Das
Pradeep Das
A proportion of all immunocompetent patients treated for visceral leishmaniasis (VL) are known to relapse; however, the risk factors for relapse are not well understood. With the support of the Rajendra Memorial Research Institute (RMRI), Médecins Sans Frontières (MSF) implemented a program in Bihar, India, using intravenous liposomal amphotericin B (Ambisome) as a first-line treatment for VL. The aim of this study was to identify risk factors for VL relapse by examining the characteristics of immunocompetent patients who relapsed following this regimen. This is an observational retrospective cohort study of all VL patients treated by the MSF program from July 2007 to August 2012. Intravenous Ambisome was administered to 8749 patients with VL in four doses of 5 mg/kg (for a total dose of 20 mg/kg) over 4–10 days, depending on the severity of disease. Out of 8588 patients not known to be HIV-positive, 8537 (99.4%) were discharged as initial cures, 24 (0.3%) defaulted, and 27 (0.3%) died during or immediately after treatment. In total, 1.4% (n = 119) of the initial cured patients re-attended the programme with parasitologically confirmed VL relapse, with a median time to relapse of 10.1 months. Male sex, age <5 years and ≥45 years, a decrease in spleen size at time of discharge of ≤0.5 cm/day, and a shorter duration of symptoms prior to seeking treatment were significantly associated with relapse. Spleen size at admission, hemoglobin level, nutritional status, and previous history of relapse were not associated with relapse. This is the largest cohort of VL patients treated with Ambisome worldwide. The risk factors for relapse included male sex, age <5 and ≥45 years, a smaller decrease in splenomegaly at discharge, and a shorter duration of symptoms prior to seeking treatment. The majority of relapses in this cohort occurred 6–12 months following treatment, suggesting that a 1-year follow-up is appropriate in future studies. Visceral leishmaniasis (VL), also known as Kala azar, accounts for the second-highest burden of parasitic disease worldwide. Fifty percent of VL cases worldwide occur in India, and up to 90% of these in the state of Bihar. Up to 10% of VL patients relapse within 6 months of treatment, particularly if co-infected with HIV. Limited data are available regarding relapse in patients with intact immune systems. Between 2007–2012, with support of the Rajendra Memorial Research Institute(RMRI), Médecins Sans Frontières (MSF) treated VL patients in Bihar with 20 mg/kg liposomal amphotericin B (Ambisome). Here we identify risk factors for relapse in immunocompetent patients by comparing the demographics and clinical characteristics of 119 patients testing negative for HIV who experienced parasitologically-confirmed VL relapse against those of the remaining 8418 patients not known to have relapsed. Male sex, age <5 years and ≥45 years, shorter duration of symptoms prior to seeking treatment, and a smaller reduction in spleen size by time of discharge were all risk factors for relapse. The majority of relapses occurred 6–12 months post-treatment with Ambisome. The conventional period of follow-up is 6 months. Considering the aim of elimination in the Indian subcontinent, this data suggests that 1-year follow-up is necessary.

31 May 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MNMohit Nair
Mohit Nair
STSantanu Tripathi
Santanu Tripathi
SMSumit Mazumdar
Sumit Mazumdar
RMRaman Mahajan
Raman Mahajan
AHAmit Harshana
Amit Harshana
SBSakib Burza
Sakib Burza
Antibiotic misuse is widespread and contributes to antibiotic resistance, especially in less regulated health systems such as India. Although informal providers are involved with substantial segments of primary healthcare, their level of knowledge, attitudes, and practices is not well documented in the literature. This quantitative study systematically examines the knowledge, attitudes, and practices of informal and formal providers with respect to antibiotic use. We surveyed a convenience sample of 384 participants (96 allopathic doctors, 96 nurses, 96 informal providers, and 96 pharmacy shopkeepers) over a period of 8 weeks from December to February using a validated questionnaire developed in Italy. Our team created an equivalent, composite KAP score for each respondent in the survey, which was subsequently compared between providers. We then performed a multivariate logistic regression analysis to estimate the odds of having a low composite score (<80) based on occupation by comparing allopathic doctors (referent category) with all other study participants. The model was adjusted for age (included as a continuous variable) and gender. Doctors scored highest in questions assessing knowledge (77.3%) and attitudes (87.3%), but performed poorly in practices (67.6%). Many doctors knew that antibiotics were not indicated for viral infections, but over 87% (n = 82) reported prescribing them in this situation. Nurses, pharmacy shopkeepers, and informal providers were more likely to perform poorly on the survey compared to allopathic doctors (OR: 10.4, 95% CI 5.4, 20.0, p<0.01). 30.8% (n = 118) of all providers relied on pharmaceutical company representatives as a major source of information about antibiotics. Our findings indicate poor knowledge and awareness of antibiotic use and functions among informal health providers, and dissonance between knowledge and practices among allopathic doctors. The nexus between allopathic doctors, pharmaceutical company representatives, and informal health providers present promising avenues for future research and intervention.

10 May 2014 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
SBSakib Burza
Sakib Burza
RMRaman Mahajan
Raman Mahajan
MSMarta Gonzalez Sanz
Marta Gonzalez Sanz
TSTemmy Sunyoto
Temmy Sunyoto
RKRanjeet Kumar
Ranjeet Kumar
MLMaría Angeles Lima
María Angeles Lima
Although human immunodeficiency virus (HIV) and visceral leishmaniasis coinfection is recognized as a major public health challenge in Africa, data regarding the prevalence in India are very limited. Consecutive HIV screening of 2077 patients aged ≥14 years with confirmed visceral leishmaniasis in Bihar, eastern India, found that 5.6% were HIV positive, including 2.4% with newly diagnosed HIV infection.

2 January 2014 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
SBSakib Burza
Sakib Burza
PSPrabhat K. Sinha
Prabhat K. Sinha
RMRaman Mahajan
Raman Mahajan
MLMaría Angeles Lima
María Angeles Lima
GMGaurab Mitra
Gaurab Mitra
PDPradeep Das
Pradeep Das
Visceral Leishmaniasis (VL; also known as Kala-azar) is an ultimately fatal disease endemic in Bihar. A 2007 observational cohort study in Bihar of 251 patients with VL treated with 20 mg/Kg intravenous liposomal amphotericin B (Ambisome) demonstrated a 98% cure rate at 6-months. Between July 2007 and August 2012, Médecins Sans Frontières (MSF) and the Rajendra Memorial Research Institute (RMRI) implemented a VL treatment project in Bihar, India—an area highly endemic for Leishmania donovani—using this regimen as first-line treatment. Intravenous Ambisome 20 mg/kg was administered in four doses of 5 mg/kg over 4–10 days, depending on the severity of disease. Initial clinical cure at discharge was defined as improved symptoms, cessation of fever, and recession of spleen enlargement. This observational retrospective cohort study describes 8749 patients with laboratory-confirmed primary VL treated over a 5-year period: 1396 at primary healthcare centers, 7189 at hospital, and 164 at treatment camps. Initial clinical cure was achieved in 99.3% of patients (8692/8749); 0.3% of patients (26/8749) defaulted from treatment and 0.4% (31/8749) died. Overall, 1.8% of patients (161/8749) were co-infected with HIV and 0.6% (51/8749) with tuberculosis. Treatment was discontinued because of severe allergic reactions in 0.1% of patients (7/8749). Overall, 27 patients (0.3%) were readmitted with post Kala-azar dermal leishmaniasis (PKDL). Risk factors for late presentation included female sex, age >15 years and being from a scheduled caste. In 2012, a long-term efficacy survey in the same area of Bihar determined relapse rates of VL after 5 years' intervention with Ambisome. Of 984 immunocompetent patients discharged between September 2010 and December 2011, 827 (84.0%) were traced in order to determine their long-term outcomes. Of these, 20 patients (2.4%) had relapsed or received further treatment for VL. Of those completing 6, 12, and 15 month follow-up, 0.3% (2/767), 3.7% (14/383), and 2.4% (4/164), respectively, had relapsed. The mean ±SD time-to-relapse was 9.6±3.0 months. This is the largest cohort of VL patients treated with 20 mg/kg Ambisome worldwide. The drug has high initial and long-term efficacy, and a low rate of adverse reactions when administered under field conditions in Bihar, India. Although challenging, its use as first line treatment in rural settings in Bihar is safe and feasible. Visceral leishmaniasis (VL), also known as Kala-azar, is a protozoan parasitic disease transmitted by phlebotomine sandflies. After malaria, VL accounts for the second-highest burden of parasitic diseases worldwide. India has half of all the VL patients worldwide, of which up to 90% are in Bihar state. Between 2007–2012, Médecins Sans Frontières (MSF) together with the Rajendra Memorial Research Institute (RMRI) supported existing health structures in Vaishali district, Bihar, by treating 8749 VL patients with intravenous liposomal amphotericin B (Ambisome) 20 mg/kg. Initial cure rate was high, with low default and mortality rates. We describe the demographic and clinical characteristics of this large patient group, including risk factors for late presentation. Ambisome can be given in short courses and is safer, better tolerated, and more effective than existing VL treatments. The MSF-supported program treated nearly 1400 ambulatory patients in rural primary healthcare centers, using existing government facilities and non-incentivized staff, demonstrating that a resource-limited healthcare system in a rural setting can meet the cold chain and human resource standards required to administer Ambisome safely. We also describe a long-term follow-up survey showing a continuing low VL relapse rate after 5 years of routine use of Ambisome. More relapses occurred after 6-month follow-up; suggesting a 12-month follow-up in future VL studies may be more appropriate.